2 citations
,
January 2015 in “BioMed Research International” This article reviews various aspects of growth factor research, highlighting their role in treatments and emphasizing the need for further clinical trials to validate their efficacy in biomedical applications.
This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.
This review analyzed clinical trials and guidelines on 5-α-reductase inhibitors (5-ARIs) and found these drugs significantly improve urinary symptoms in BPH and stabilize hair loss in androgenic alopecia, but may cause sexual dysfunction and gynecomastia.
July 2025 in “Saudi Journal of Medicine and Public Health” In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.
July 2024 in “Clinical Cosmetic and Investigational Dermatology” In this review, the authors summarized non-pharmacological therapies that may promote hair growth and regeneration as alternatives to traditional drug treatments and hair transplantation, both of which have notable limitations.